adventistworld.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adventistworld.org Daily Mail and Mail on Sunday newspapers.
Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, shares insight on the cost-effectiveness and utility of biomarker testing in non–small cell lung cancer (NSCLC).
Genelux (GNLX) Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shared his thoughts on the most important recent advances in non–small cell lung cancer (NSCLC), including a better understanding of patients who may benefit from immunotherapy.
Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).